Gyeongnam Biopharma Decides on 10 Billion KRW Paid-in Capital Increase

[Asia Economy Reporter Lee Gwan-joo] Gyeongnam Biopharma announced on the 10th that it has decided to conduct a paid-in capital increase through a third-party allotment to raise 10 billion KRW in operating funds. The new shares consist of 5,194,805 common shares, with a par value of 500 KRW per share.